TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer

Oncogene

Volumn 32, Issue 16, 2013, Pages 2005-2015

  Wendt, M K ^a   Schiemann, B J ^a   Parvani, J G ^a   Lee, Y H ^a   Kang, Y ^b   Schiemann, W P ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

EMT; FAK; metastasis; Pyk2; signal transduction; TGF

Indexed keywords

BETA1 INTEGRIN; FOCAL ADHESION KINASE 2; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INVASION; CELL ISOLATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOCAL ADHESION KINASE 2; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SRC-FAMILY KINASES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS;

EID: 84876671506     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.230     Document Type: Article

References (58)

1. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-b. Future Oncol 2009; 5: 1145-1168.
2. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010; 15: 169-190.
3. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010; 29: 6485-6498.
4. Wendt MK, Taylor MA, Schiemann BJ, Schiemann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 2011; 22: 2423-2435.
5. Lipinski CA, Loftus JC. Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets 2010; 14: 95-108.
6. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 2010; 123: 1007-1013.
7. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-defi-cient mice. Nature 1995; 377: 539-544.
8. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP et al. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci USA. 2003; 100: 10740-10745.
9. Schaller MD, Sasaki T. Differential signaling by the focal adhesion kinase and cell adhesion kinase beta. J Biol Chem 1997; 272: 25319-25325.
10. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM et al. Protein tyrosine kinase PYK2 involved in Ca(2 +)-induced regulation of ion channel and MAP kinase functions. Nature 1995; 376: 737-745.
11. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996; 383: 547-550.
12. Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, Keydar I et al. RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 2000; 19: 1318-1328.
13. Fan H, Guan JL. Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J Biol Chem 2011; 286: 18573-18582.
14. Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, Poon RT et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One 2011; 6: e18878.
15. Weis SM, Lim S-T, Lutu-Fuga KM, Barnes LA, Chen XL, Gothert JR et al. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol 2008; 181: 43-50.
16. Sieg DJ, Ilic D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK-cell migration. Embo J. 1998; 17: 5933-5947.
17. Nakamura K, Yano H, Schaefer E, Sabe H. Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies. Oncogene 2001; 20: 2626-2635.
18. Wendt M, Schiemann W. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 2009; 11: R68.
19. Judson PL, He X, Cance WG. Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999; 86: 1551-1556.
20. Kim SJ, Park JW, Yoon JS, Mok JO, Kim YJ, Park HK et al. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study. J Korean Med Sci 2004; 19: 710-715.
21. Lightfoot Jr HM, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L et al. Upre-gulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 2004; 88: 109-116.
22. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 2006; 53: 263-271.
23. Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA et al. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol 2008; 173: 1540-1550.
24. Burdick AD, Ivnitski-Steele ID, Lauer FT, Burchiel SW. PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells. Carcinogenesis 2006; 27: 2331-2340.
25. Avsian-Kretchmer O, Hsueh AJ. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol Endocrinol 2004; 18: 1-12.
26. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
27. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA. 2009; 106: 10290-10295.
28. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562, 271. Cancer Res 2008; 68: 1935-1944.
29. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C et al. Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor. J Biol Chem 2007; 282: 14845-14852.
30. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
31. Galliher AJ, Schiemann WP. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2006; 8: R42.
32. Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor-beta in cancer progression. Future Oncol 2006; 2: 743-763.
33. Galliher-Beckley AJ, Schiemann WP. Grb2 binding to Tyr284 in TbR-II is essential for mammary tumor growth and metastasis stimulated by TGF-b. Carcinogenesis 2008; 29: 244-251.
34. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chro-matin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
35. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA. 2010; 107: 15449-15454.
36. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009; 106: 13820-13825.
37. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
38. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004; 6: 154-161.
39. Llic Dk, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-defi-cient mice. Nature 1995; 377: 539-544.
40. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 2008; 68: 6241-6250.
41. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 2010; 70: 5706-5716.
42. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
43. Dahl U, Sjodin A, Semb H. Cadherins regulate aggregation of pancreatic beta-cells in vivo. Development 1996; 122: 2895-2902.
44. Wendt MK, Smith JA, Schiemann WP. p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 2009; 284: 34145-34156.
45. Parvani JG, Taylor MA, Schiemann WP, Noncanonical TGF-b. Signaling During Mammary Tumorigenesis. J Mammary Gland Biol Neoplasia 2011; 16: 127-146.
46. Wendt MK, Molter J, Flask CA, Schiemann WP. In vivo Dual Substrate Biolumi-nesent Imaging. J Vis Exp 2011; pii:3245 (doi:10.3791/3245).
47. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-1108.
48. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007; 67: 3752-3758.
49. Ungefroren H, Sebens S, Groth S, Gieseler F. Fandrich F. The Src family kinase inhibitors PP2 and PP1 block TGF-b1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-b receptors. Curr Cancer Drug Targets 2011; 11: 524-535.
50. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 2005; 102: 13909-13914.
51. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
52. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009.
53. Lim S-T, Chen XL, Lim Y, Hanson DA, Vo T-T, Howerton K et al. Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation. Mol Cell 2008; 29: 9-22.
54. Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. J Biol Chem 2010; 285: 1743-1753.
55. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 44-55.
56. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
57. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361: 1590-1596.
58. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.